🟢 Pyxis Oncology is trading 10% up in after-hours trading after naming Thomas Civik CEO and chairman

Pyxis Oncology is trading 10.01% up at $4.28 in after-hours trading after announcing Thomas Civik’s appointment as permanent CEO and chairman, effective September 4, 2026.

• Civik had served as interim CEO since February; co-founder John Flavin became lead independent director.
• A September 9 webcast is scheduled to present updated MICVO Phase 1 data, offering a potential near-term clinical catalyst.
• The announcement was reported September 8 by BioSpace and confirmed in an SEC filing.